7:20 am Morning Networking Coffee

8:20 am Chairperson’s Opening Remarks

  • Brian Sullivan Principal Scientist - Vaccines and Immunology, Arcturus Therapeutics

Driving the Vision & Success of Next Generation mRNA-Based Vaccines for Infectious Diseases

8:30 am mRNA Vaccines for a Pandemic Response

  • Brett Leav Head, Clinical Development; Public Health Vaccines, Moderna


  • Introduce prototype pandemic pathogen framework
  • Zika vaccine development as model prototype pathogen

9:00 am Sa-mRNA Influenza Vaccines Provide Multiple Potential Layers of Protection Against Influenza

  • Yingxia Wen Senior Director; Head of Discovery Research, Seqirus


  • Influenza is a complicated virus with multiple co-circulating and evolving strains which makes for a challenging vaccine target
  • Sa-mRNA vaccines can generate robust B-cell and T-cell responses
  • Robust CD8+ T-cell responses add another layer of protection over the more standard antibody responses that generate protection with current vaccines

9:30 am Next Generation Technologies for Broad Application of mRNA Vaccines

  • Jeffrey Ulmer Chief Scientific Advisor, Immorna Biotherapeutics


  • Lessons learned from COVID-19
  • Addressing key limitations of current mRNA vaccines
  • Potential for application beyond preventive vaccines

10:00 am Boost Your Vaccine Manufacturing: Accelerating for a Rapid Response

  • Joe Makowiecki Director of Business Development, Enterprise Solutions, Cytiva


  • The clinical promise of mRNA therapeutics and vaccines is clear, but their novelty also brings new challenges to the
    manufacturing process
  • Strategies and technologies for advancing and accelerating vaccine manufacturing
  • How to address the challenges of developing a robust, optimized, scalable, and integrated mRNA manufacturing process

10:30 am Morning Networking Break

12:30 pm Networking Lunch Break

3:00 pm Afternoon Networking Break

Achieving a Successful Route to Equitable Distribution for mRNA-Based Therapeutics & Vaccines

3:30 pm Building mRNA Vaccine Capacity in LMICs

  • Cristina Bruno Program Manager - mRNA Technology Transfer , World Health Organization


  • Pandemic has highlighted inequity in terms of access between regions with vaccine manufacturing capacities and region with none. Following COVID-19 massive demands from LMICs for access to mRNA technology know-how and manufacturing capacity has raised
  • Multiple initiatives are underway to transfer mRNA technology to LMICs challenging with sustainability of infrastructures and know-how in absence of routine market. Minimize the risks of “build and bust” by careful evaluation of costs (CAPEX and OPEX) is essential
  • Development of mRNA vaccines against disease of LMICs importance (e.g. TB, HIV, malaria) can contribute to capacity sustainability and pandemic preparedness


4:00 pm mRNA-Based Therapeutics & Vaccines: Driving a Shift in the Commercial Model

  • Jane True VP - mRNA Commercial Development, Pfizer


  • mRNA technology has potential for faster product design and easier-to-scale manufacturing: how this expands therapeutic and vaccine possibilities
  • The potential for speed and scale in development puts pressure on commercial organizations to be more agile, potentially changing the conversation with HCPs and on global equity in healthcare
  • Potential evolution of enabling factors that support faster-to-market therapies and vaccines: data generation, digitization, regulatory harmonization, etc

4:30 pm mRNA-Based Vaccines & Delivery of Abs for Global Health Diseases

  • Pervin Anklesaria Deputy Director - HIV Vaccines & Biologics , Bill & Melinda Gates Foundation


  • Importance of mRNA platform in vaccines for global health diseases for underrepresented populations and countries
  • Our portfolio of potential products/vaccines
  • Future strategic directions

4:50 pm Achieving Equitable Access to CAR-T & Other Cellular Therapy Through RNA Engineering


  • Use of DNA-based cell therapy approaches is limited to academic medical centers in high-income countries due to high costs of manufacturing as well as the level of clinical care needed to manage toxicities
  • RNA-engineered cellular therapy is less expensive to manufacture, less complex to prepare and administer and has less potential for significant short and long-term toxicity
  • Cartesian Therapeutics has successfully used three different mRNA-engineered cell therapy products in community clinics around the US, as well as in academic centers in a low/medium-income country, demonstrating the potential of RNA to make global distribution of effective clinical therapies more equitable

5:15 pm
Chair’s Closing Remarks & End of 2nd Annual mRNA-Based Therapeutics Summit 2022

  • Manmohan Singh SVP - Pharmaceutical Sciences & Delivery Technologies, Beam Therapeutics